Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China.
CNS Drugs. 2017 Jul;31(7):535-549. doi: 10.1007/s40263-017-0431-2.
The mechanistic target of rapamycin (mTOR) is an important molecule that connects aging, lifespan, energy balance, glucose and lipid metabolism, and neurodegeneration. Rapamycin exerts effects in numerous biological activities via its target protein, playing a key role in energy balance, regulation of autophagy, extension of lifespan, immunosuppression, and protection against neurodegeneration. There are many similar pathophysiological processes and molecular pathways between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), and pharmacologic agents used to treat T2DM, including glucagon-like peptide-1 (GLP-1) analogs, seem to be beneficial for AD. mTOR mediates the effects of GLP-1 analogs in the treatment of T2DM; hence, I hypothesize that mTOR is a key molecule for mediating the protective effects of GLP-1 for AD.
雷帕霉素靶蛋白（mTOR）是一个重要的分子，它连接着衰老、寿命、能量平衡、葡萄糖和脂质代谢以及神经退行性变。雷帕霉素通过其靶蛋白发挥多种生物活性作用，在能量平衡、自噬调节、寿命延长、免疫抑制和神经退行性变保护中发挥关键作用。阿尔茨海默病（AD）和 2 型糖尿病（T2DM）之间存在许多相似的病理生理过程和分子途径，用于治疗 T2DM 的药物，包括胰高血糖素样肽-1（GLP-1）类似物，似乎对 AD 有益。mTOR 介导 GLP-1 类似物在治疗 T2DM 中的作用；因此，我假设 mTOR 是介导 GLP-1 对 AD 保护作用的关键分子。
